141 related articles for article (PubMed ID: 33913609)
1. Characterization of kaposiform lymphangiomatosis tissue-derived cells.
Nozawa A; Ozeki M; Yasue S; Endo S; Noguchi K; Kanayama T; Tomita H; Aoki Y; Ohnishi H
Pediatr Blood Cancer; 2021 Oct; 68(10):e29086. PubMed ID: 33913609
[TBL] [Abstract][Full Text] [Related]
2. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Boscolo E; Pastura P; Glaser K; Goines J; Hammill AM; Adams DM; Dickie P; Hsi Dickie B; Le Cras TD
Pediatr Blood Cancer; 2019 Aug; 66(8):e27790. PubMed ID: 31045327
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):1911-1915. PubMed ID: 35246606
[TBL] [Abstract][Full Text] [Related]
4. Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.
Ozeki M; Aoki Y; Nozawa A; Yasue S; Endo S; Hori Y; Matsuoka K; Niihori T; Funayama R; Shirota M; Nakayama K; Fukao T
Orphanet J Rare Dis; 2019 Sep; 14(1):215. PubMed ID: 31511039
[TBL] [Abstract][Full Text] [Related]
5. Changes in cell morphology and function induced by the NRAS Q61R mutation in lymphatic endothelial cells.
Yasue S; Ozeki M; Nozawa A; Endo S; Ohnishi H
PLoS One; 2024; 19(5):e0289187. PubMed ID: 38809881
[TBL] [Abstract][Full Text] [Related]
6. NRAS
Pastura P; McDaniel CG; Alharbi S; Fox D; Coleman B; Malik P; Adams DM; Le Cras TD
Pediatr Blood Cancer; 2024 Jul; 71(7):e31032. PubMed ID: 38711167
[TBL] [Abstract][Full Text] [Related]
7. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
Barclay SF; Inman KW; Luks VL; McIntyre JB; Al-Ibraheemi A; Church AJ; Perez-Atayde AR; Mangray S; Jeng M; Kreimer SR; Walker L; Fishman SJ; Alomari AI; Chaudry G; Trenor Iii CC; Adams D; Kozakewich HPW; Kurek KC
Genet Med; 2019 Jul; 21(7):1517-1524. PubMed ID: 30542204
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic endothelial cell-specific NRAS p.Q61R mutant embryos show abnormal lymphatic vessel morphogenesis.
Nozawa A; Abe T; Niihori T; Ozeki M; Aoki Y; Ohnishi H
Hum Mol Genet; 2024 May; ():. PubMed ID: 38743908
[TBL] [Abstract][Full Text] [Related]
9. Kaposiform lymphangiomatosis effectively treated with MEK inhibition.
Foster JB; Li D; March ME; Sheppard SE; Adams DM; Hakonarson H; Dori Y
EMBO Mol Med; 2020 Oct; 12(10):e12324. PubMed ID: 32894644
[TBL] [Abstract][Full Text] [Related]
10. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
12. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
13. Proliferative Cells From Kaposiform Lymphangiomatosis Lesions Resemble Mesenchyme Stem Cell-like Pericytes Defective in Vessel Formation.
Glaser K; Dickie P; Dickie BH
J Pediatr Hematol Oncol; 2018 Nov; 40(8):e495-e504. PubMed ID: 30256265
[TBL] [Abstract][Full Text] [Related]
14. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
15. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.
Rosenberg L; Yoon CH; Sharma G; Bertagnolli MM; Cho NL
Carcinogenesis; 2018 May; 39(5):681-688. PubMed ID: 29538717
[TBL] [Abstract][Full Text] [Related]
17. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.
Campbell M; Allen WE; Sawyer C; Vanhaesebroeck B; Trimble ER
Circ Res; 2004 Aug; 95(4):380-8. PubMed ID: 15242975
[TBL] [Abstract][Full Text] [Related]
18. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
Boscolo E; Coma S; Luks VL; Greene AK; Klagsbrun M; Warman ML; Bischoff J
Angiogenesis; 2015 Apr; 18(2):151-62. PubMed ID: 25424831
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers of kaposiform lymphangiomatosis.
Ozeki M; Nozawa A; Kawamoto N; Fujino A; Hirakawa S; Fukao T
Pediatr Blood Cancer; 2019 Sep; 66(9):e27878. PubMed ID: 31207041
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
